Dry Mouth Clinical Trial
Official title:
A Pilot Clinical Study to Assess Dry Mouth Relief After Using an Experimental Mouth Rinse Compared to a Negative Control
Verified date | January 2021 |
Source | Procter and Gamble |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of this pilot study is to determine if an experimental mouth rinse and a marketed dry mouth rinse are more effective in relieving dry mouth compared to water.
Status | Completed |
Enrollment | 22 |
Est. completion date | December 5, 2019 |
Est. primary completion date | December 5, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Provide written informed consent prior to participation and be given a signed copy of the informed consent form; - Be at least 18 years of age; - Be in good general health as determined by the Investigator/designee; - Agree not to participate in any other oral care studies for the duration of this study; - Agree to delay elective dentistry, including dental prophylaxis, until study completion, and to report any non-study dentistry received during the course of the study; - Agree to refrain from the use of any non-study oral hygiene products for the study duration including mouth rinse and toothpaste (flossing is permitted if part of their normal routine); - Self-report a dry mouth feeling according to the modified DMI questions. (Subject must answer at least 2 out of 4 questions with 'agree a little,' 'agree' or 'strongly agree'); - Agree to refrain from smoking, drinking, using tobacco products, using breath mints, medicated lozenges, or chewing gum during the 4-hour test period; - Agree to return for all scheduled visits and to follow all study procedures. Exclusion Criteria: - Any condition or disease, as determined by the Investigator/Designee, that could be expected to interfere with examination procedures, with compliance, or with the subject's safe completion of the study; - Severe periodontal disease, as characterized by purulent exudate, generalized mobility, and/or severe recession; - Active treatment for periodontitis; - Having a history of allergies or hypersensitivity to mouth rinse or ingredients in commercial dental products or cosmetics; - Self-reported pregnancy or the intent to become pregnant during the study, or breast feeding; - Full or partial dentures or any orthodontic appliances such as braces or aligners, or tongue or mouth piercing; - Having diabetes; - Inability to undergo any study procedure; - Having untreated oral mucosal disease which in the opinion of the investigator could interfere with the study (e.g., current oral ulceration); - Use of prescription systemic parasympathetic medications (e.g., Pilocarpine), for the treatment of the feeling of dry mouth; - Currently under the care of a dental/medical professional specifically for the treatment of dry mouth (at the discretion of the Investigator/Designee); - Self-reported mouth breathers (i.e., mouth breathing secondary to nasal obstruction); - Evidence of gross intra-oral neglect or need for extensive dental therapy; or - Currently undergoing radiotherapy and/or chemotherapy treatment. |
Country | Name | City | State |
---|---|---|---|
United States | Procter & Gamble | Mason | Ohio |
Lead Sponsor | Collaborator |
---|---|
Procter and Gamble |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Product Performance and Attributes (PPAQ I) Question #1: 2-hr at Day 4 | Product Performance and Attributes (PPAQ I) Question #1:
Since you have been used the product, please rate each of the following at this timepoint: (Select one response for each attribute)- excellent=5, very good=4, good=3, fair=2, poor=1: 1) Relieves the discomfort of your dry mouth |
2-hour, Day 4 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04914208 -
Effect of Wearing Face Masks on Salivary Parameters and Halitosis
|
N/A | |
Completed |
NCT00601211 -
Bioequivalency Study of 5 mg Piolocarpine Tablets Under Fed Conditions
|
N/A | |
Completed |
NCT00601874 -
Bioequivalency Study of 5 mg Pilocarpine Tablets Under Fasting Conditions
|
N/A | |
Completed |
NCT03215251 -
Effectiveness of an Intervention Bundle on Thirst Intensity and Dry Mouth Among Patients in ICUs
|
N/A | |
Completed |
NCT04632004 -
Questionnaire Regarding the Effect of Wearing Face Masks on Oral Health
|
N/A | |
Completed |
NCT05640362 -
Efficacy of Natural Enzymes Mouthwash: a Randomised Controlled Trial
|
N/A | |
Not yet recruiting |
NCT06412627 -
The Effect of Intervention About Dry Mouth and Thirst in Patients With Endotracheal Tube
|
N/A | |
Completed |
NCT04986501 -
Clinical Evaluation of MucoPEG™ for Xerostomia
|
N/A | |
Completed |
NCT04189081 -
Improvement of Dry Mouth Sufferers After Using an Experimental Dry Mouth Rinse Compared to a Water Control
|
N/A | |
Completed |
NCT05871580 -
Effect to the Photobiomodulation in the Burning Mouth Syndrome
|
N/A | |
Completed |
NCT06258603 -
Oral Care of Intubated Intensive Care Patient
|
N/A | |
Completed |
NCT01647737 -
Green Tea Lozenges for the Management of Dry Mouth
|
Phase 1/Phase 2 | |
Completed |
NCT01737307 -
Effect of Fluoride Varnish and CPP-ACP on Oral and Salivary Symptoms During Chemotherapy
|
Phase 2 | |
Active, not recruiting |
NCT03874572 -
Allogeneic Mesenchymal Stem Cells for Radiation-induced Hyposalivation and Xerostomia/Dry Mouth
|
Phase 1 | |
Completed |
NCT03035825 -
Efficacy of Oral Moisturizing Jelly on Oral Health and Nutrition in Post-radiotherapy Head and Neck Cancer Patients
|
N/A | |
Recruiting |
NCT05964959 -
A Mouth Education Program for Dry Mouth
|
N/A | |
Withdrawn |
NCT02123147 -
Examining the Immunological Process of Autoimmune Patients
|
N/A | |
Completed |
NCT01885065 -
Efficacy of Novel Edible Gel-based Artificial Saliva in Cancer Patients
|
N/A | |
Completed |
NCT03281486 -
"Hyaluronan" Formulation for Type 2 Diabetic Patients With Dry Mouth
|
N/A | |
Not yet recruiting |
NCT05506137 -
Xerostomia in Patients With a Life-limiting Condition or Frailty
|
Phase 3 |